297 related articles for article (PubMed ID: 37762206)
1. The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.
Adinolfi E; De Marchi E; Grignolo M; Szymczak B; Pegoraro A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762206
[TBL] [Abstract][Full Text] [Related]
2. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
3. P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells.
Pegoraro A; De Marchi E; Ferracin M; Orioli E; Zanoni M; Bassi C; Tesei A; Capece M; Dika E; Negrini M; Di Virgilio F; Adinolfi E
Cell Death Dis; 2021 Nov; 12(12):1088. PubMed ID: 34789738
[TBL] [Abstract][Full Text] [Related]
4. P2X7 Variants in Oncogenesis.
Pegoraro A; De Marchi E; Adinolfi E
Cells; 2021 Jan; 10(1):. PubMed ID: 33477845
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.
Cortés-Garcia JD; López-López C; Cortez-Espinosa N; García-Hernández MH; Guzmán-Flores JM; Layseca-Espinosa E; Portales-Cervantes L; Portales-Pérez DP
Immunobiology; 2016 Jan; 221(1):84-93. PubMed ID: 26307000
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
7. Uncaria tomentosa extract alters the catabolism of adenine nucleotides and expression of ecto-5'-nucleotidase/CD73 and P2X7 and A1 receptors in the MDA-MB-231 cell line.
Santos KF; Gutierres JM; Pillat MM; Rissi VB; Santos Araújo MD; Bertol G; Gonçalves PB; Schetinger MR; Morsch VM
J Ethnopharmacol; 2016 Dec; 194():108-116. PubMed ID: 27590731
[TBL] [Abstract][Full Text] [Related]
8. Administration of P2X7 Receptor Blockers in Oncological Experimental Models.
De Marchi E; Pegoraro A; Adinolfi E
Methods Mol Biol; 2022; 2510():303-314. PubMed ID: 35776333
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Li XY; Moesta AK; Xiao C; Nakamura K; Casey M; Zhang H; Madore J; Lepletier A; Aguilera AR; Sundarrajan A; Jacoberger-Foissac C; Wong C; Dela Cruz T; Welch M; Lerner AG; Spatola BN; Soros VB; Corbin J; Anderson AC; Effern M; Hölzel M; Robson SC; Johnston RL; Waddell N; Smith C; Bald T; Geetha N; Beers C; Teng MWL; Smyth MJ
Cancer Discov; 2019 Dec; 9(12):1754-1773. PubMed ID: 31699796
[TBL] [Abstract][Full Text] [Related]
10. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
11. P2X7 receptor activation increases expression of caveolin-1 and formation of macrophage lipid rafts, thereby boosting CD39 activity.
Savio LEB; de Andrade Mello P; Santos SACS; de Sousa JC; Oliveira SDS; Minshall RD; Kurtenbach E; Wu Y; Longhi MS; Robson SC; Coutinho-Silva R
J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 32005701
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.
de Andrade Mello P; Bian S; Savio LEB; Zhang H; Zhang J; Junger W; Wink MR; Lenz G; Buffon A; Wu Y; Robson SC
Oncotarget; 2017 Sep; 8(40):67254-67268. PubMed ID: 28978031
[TBL] [Abstract][Full Text] [Related]
13. Extracellular purines, purinergic receptors and tumor growth.
Di Virgilio F; Adinolfi E
Oncogene; 2017 Jan; 36(3):293-303. PubMed ID: 27321181
[TBL] [Abstract][Full Text] [Related]
14. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Horenstein AL; Bracci C; Morandi F; Malavasi F
Front Immunol; 2019; 10():760. PubMed ID: 31068926
[TBL] [Abstract][Full Text] [Related]
15. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
16. The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy.
Kang C; Liu L; Wu C; Li L; Jia X; Xie W; Chen S; Wu X; Zheng H; Liu J; Li R; Zeng B
Front Immunol; 2023; 14():1111369. PubMed ID: 36911717
[TBL] [Abstract][Full Text] [Related]
17. A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice.
De Marchi E; Pegoraro A; Turiello R; Di Virgilio F; Morello S; Adinolfi E
Front Cell Dev Biol; 2022; 10():876510. PubMed ID: 35663396
[TBL] [Abstract][Full Text] [Related]
18. The P2X7 Receptor in Tumor Immunity.
Grassi F; De Ponte Conti B
Front Cell Dev Biol; 2021; 9():694831. PubMed ID: 34239877
[TBL] [Abstract][Full Text] [Related]
19. P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses.
Orioli E; De Marchi E; Giuliani AL; Adinolfi E
Curr Med Chem; 2017; 24(21):2261-2275. PubMed ID: 28266268
[TBL] [Abstract][Full Text] [Related]
20. [Identification of a new pro-invasion factor in tumor microenvironment: progress in function and mechanism of extracellular ATP].
Fang WG; Tian XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):188-195. PubMed ID: 28416823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
